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A Point Mutation in HLA-A*0201 Results in
Failure to Bind the TAP Complex and to
Present Virus-Derived Peptides to CTL
Amy L. Peace-Brewer,* Lynda G. Tussey,* these cell lines maps to the Tap1 and Tap2 genes en-
coded within the class II region of the MHC (DeversonMasanori Matsui,* Guoxuan Li,²
Daniel G. Quinn,* and Jeffrey A. Frelinger* et al., 1990; Monaco et al., 1990; Spies et al., 1990;
Trowsdale et al., 1990). These two gene products form*Department of Microbiology and Immunology
²Linberger Comprehensive Cancer Center the heterodimeric TAP complex (Kelly et al., 1992; Spies
et al., 1992). The binding of peptides to class I moleculesUniversity of North Carolina
Chapel Hill, North Carolina 27599-7290 is thought to be facilitated by association of assembled
heavy chain±b2m heterodimers with the TAP complex
(Ortmann et al., 1994; Suh et al., 1994). TAP mutant cell
lines, which are defective in the delivery of peptides intoSummary
the ER, fail to present endogenously derived peptide to
CTL (Cerundolo et al., 1990; Hosken and Bevan, 1990;Mutating the HLA-A*0201 heavy chain from threonine
Spies et al., 1992) and have reduced cell surface expres-to lysine at position 134 (T134K) results in a molecule
sion of conformed MHC class I molecules (Cerundolothat presents exogenous peptide, but cannot present
et al., 1990; DeMars et al., 1985; Kelly et al., 1992; Ljung-endogenously derived antigen. This is reflected in di-
gren et al., 1990; Salter and Cresswell, 1986; Spies etminished cell surface expression and altered intracel-
al., 1992; Townsend et al., 1989). Surface expression oflular trafficking of T134K. The failure of T134K to pres-
class I molecules on these cells can be increased byent endogenous antigen can be overcome by using an
addition of exogenous peptide of appropriate length andER targeting sequence, suggesting that the antigen
restriction (Cerundolo et al., 1990; Schumacher et al.,presentation defect is restricted to TAP-dependent
1990; Townsend et al., 1989). The inability of newly syn-peptide loading. The ability of T134K to load peptide
thesized class I heavy chain±b2m complex to load pep-in a TAP-dependent manner is dramatically reduced
tide in a TAP-dependent manner in these cell lines alsocompared with HLA-A*0201. By coimmunoprecipita-
results in the generation of unstable MHC class I com-tion there is no detectable association of the T134K
plexes. These unstable complexes are detectable in themolecule with the TAP complex. Thus, T134K selec-
ER, Golgi, and on the cell surface (Baas et al., 1992).tively affects TAP association and peptide loading,
TAP-deficient cell lines expressing HLA-A*0201 (A2.1),suggesting a requirement for the direct interaction of
such as T2, express increased levels of A2.1 complexesMHC class I heavy chain and the TAP complex for
on the cell surface compared with other class I proteinsefficient presentation of endogenous antigen.
produced by these cell lines (DeMars et al., 1985; Salter
and Cresswell, 1986). Analysis of the A2.1-associated
peptides from T2 revealed a predominance of peptides
derived from signal sequences (Henderson et al., 1992;Introduction
Wei and Cresswell, 1992). This demonstrates that, in the
case of A2.1, a second pathway of intracellular peptideMajor histocompatibility complex (MHC) class I mole-
loading exists that is independent of the TAP complex.cules present endogenously derived antigen to cyto-
Threonine at position 134 is invariant among rat, mu-toxic T lymphocytes (CTL) (Townsend et al., 1985). This
rine, and human class I alleles. Analysis of the crystalprocess is critical for the recognition of virally infected
structure of the A2.1 molecule indicates that this residueor transformed cells as well as for the selection of the
is located on a solvent-exposed loop between b strandsT cell repertoire (Germain, 1994). Stable assembly and
(Bjorkman et al., 1987). No interaction with other do-transport to the cell surface of the MHC class I molecule
mains of the molecule is predicted. In this study, werequires association of the heavy chain with b2-micro-
have examined a point mutation of threonine 134 toglobulin (b2m) and peptide within the lumen of the endo- lysine (T134K) in the A2.1 molecule. The experimentsplasmic reticulum (ER) (Bijlmakers and Ploegh, 1993;
presented here show that the T134K mutation affectsNeefjes et al., 1993; Townsend et al., 1989). The peptides
the class Iantigen processing and presentation pathwayassociating with MHC class I molecules are generally
at the critical point of TAP-dependent peptide loading.derived from endogenously synthesized proteins and
are usually 8±10 aa in length (Falk et al., 1991). Once
assembled, the MHC class I complex traffics from the Results
endoplasmic reticulum to the cell surface via the secre-
tory pathway (Germain, 1994). Effect of Mutation of Threonine 134 on Cell
Surface ExpressionA critical juncture in the class I antigen processing
and presentation pathway is the delivery of peptide into The cell surface expression of A2.1 and T134K was
quantitated by flow cytometry using the conformation-the lumen of the ER (Androlewicz et al., 1993; Andro-
lewicz and Cresswell, 1994; Neefjes et al., 1993; Shep- sensitive antibody BB7.2, or HCA2, a monoclonal anti-
body that detects free HLA-A heavy chain (H. Ploegh,herd et al., 1993). The crucial role of the transporter
associated with T cell antigen processing (TAP) complex personal communication) (Figure 1). The level of BB7.2-
reactive complexes on the surface of C1R±T134K wasin this process has been demonstrated by analysis of
a number of mutant cell lines. The genetic defect in substantially less (20% relative expression) than that on
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Analysis of the Rate of Intracellular Transport
To determine the reason for the aberrant cell surface
expression by C1R±T134K, transport of the molecules
to the cell surface was examined. The intracellular traf-
ficking of class I molecules was investigated by examin-
ing the acquisition of endoglycosidase H (endo H) resis-
tance of T134K and A2.1 using pulse±chase analysis.
Figures 2A and 2C show the phosphorimage scans of
immunoprecipitates from C1R±A2.1 and C1R±T134K,
respectively. The number of pixels contained within
each band is shown in Figures 2B and 2D. The half time
of trafficking (t 1/2), i.e., the time required for half the
class I molecules to acquire endo H resistance, is 40
min for the A2.1 molecules (Figure 2B), while the t 1/2
of trafficking for T134K molecules is 12 min (Figure 2D).
Interestingly, the amount of radiolabeled complexes im-
munoprecipitatable with BB7.2 from the C1R±T134K ly-
sates decreases over time. Similar results were alsoFigure 1. Cell Surface Expression
found using the W6/32 antibody (data not shown).The percentage of (A) BB7.2-reactive complexesexpressed on C1R±
T134K relative to C1R±A2.1 is significantly lower, while the percent- To analyze further the apparent loss of T134K com-
age of (B) HCA2-reactive forms is dramatically increased. Cells were plexes over time, radiolabeled extracts at various chase
incubated with either HCA2 or BB7.2 followed by FACS analysis. timepoints were subjected to sequential immunoprecip-
Expression of the BB7.2 or HCA2-reactive forms is shown relative itation. The heavy chain±b2m±peptide complexes wereto C1R±A2.1 by the closed bars.
first removed using BB7.2 and then the remaining heavy
chain complexes were precipitated using UCSF2. As a
control, the TAP-negative A2.1-positive T2 cell line was
C1R±A2.1 (Figure 1A). In contrast, the level of HCA2- included. The resulting immunoprecipitates were ana-
reactive forms on C1R±T134K was increased 2.8-fold lyzed by isoelectric focusing. This enables the matura-
over that detectable on C1R±A2.1 (Figure 1B). Since tion of the A2.1 molecules to be examined specifically,
C1R±T134K transfectants synthesize approximately since UCSF2 cross-reacts with other class I alleles, as
50% more heavy chain than C1R±A2.1, the discrepancy well as determination of the rate of transport to the
in cell surface expression is not the result of limiting trans±Golgi. Modification of the carbohydrate chain by
heavy chain synthesis (see Figure 9, lanes 3 and 6). sialyltransferases has been localized to the trans±Golgi
Overall, the expression of MHC molecules on C1R± network. The negatively charged sialic acid moieties
T134K shows a marked increase in the proportion of result in a shift of the class I antigen toward the more
acidic position on the gel. The positions of the 0, 1, andfree heavy chain compared with C1R±A2.1.
Figure 2. Acquisition of Endo H Resistance Is Altered in C1R±T134K
(A) C1R±A2.1 and (C) C1R±T134K, respectively, were assayed for acquisition of endo H resistance using pulse±chase. Shown are the resulting
phosphorimage scans. Cells were metabolically labeled for 5 min followed by incubation for the indicated chase times. Immunoprecipitations
were carried out using BB7.2. Plus indicates digestion with endo H; minus indicates mock digestion. Immunoprecipitates were resolved by
12% SDS±PAGE under reducing conditions.
(B) C1R±A2.1 and (D) C1R±T134K. Graphic representation of the amount of radiolabel contained within the endo H±resistant (solid line) and
sensitive bands (dashed line) at each chase timepoint shown in (A) and (C). Analysis was performed using the ImageQuant software. Level
of radiolabel present in each band is expressed in terms of pixels.
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Figure 3. Analysis of the Rate of Appearance of BB7.2-Reactive Forms in the trans±Golgi
Phosphorimage scans of isoelectric focusing gels resulting from sequential immunoprecipitation from C1R±A2.1 (A), C1R±T134K (B), and T2
(C) with BB7.2 followed by UCSF2 in pulse±chase experiments. Brackets indicate position of the A2.1 heavy chain and b2m; 0, 1, and 2 indicate
the position of the different sialyated forms of the heavy chain. Additional bands in the UCSF2 precipitates of T2 correspond to expression
of the HLA-B5 allele by this cell line.
2 sialylated forms for A2.1, T134K, and A2.1 expressed Quantitation of the immunoprecipitates derived from ei-
ther C1R±T134K or T2 (Figures 4B and 4C, respectively)in T2 (A2.T2) are noted on the phosphorimager scans
(Figures 3A, 3B, and 3C). As a result of the net charge suggests that for a short period of time (less than 30
min) there is formation of heavy chain±b2m±peptidechange in the A2.1 molecule due to the mutation of
threonine to lysine, the 0, 1, and 2 sialic acid forms of complexes, as indicated by the decrease in the total
UCSF2 precipitate and the increase in BB7.2-reactiveT134K migrate to different positions than that observed
for A2.1. forms. However, the percentageof BB7.2-reactiveforms
in relation to the UCSF2 forms differs substantially fromThe rate of appearance of BB7.2-immunoprecipitable
forms of T134K and A2.T2 in the trans±Golgi network that observed for A2.1. Furthermore, at later chase time-
points, a decline in BB7.2 forms suggests the disappear-was much faster than that of A2.1, with T134K being
slightly faster than T2. The estimated half-time of trans- ance of the BB7.2 epitope. However, the concomitant
increase in UCSF2 forms indicates a loss of conforma-port for A2.1 and T134K was 43 min and 17 min, respec-
tively (Figure 3), in agreement with the half-time of trans- tion rather than degradation of the molecules.
It is possible that the presence of very faint b2m bandsport from the ER to the cis±Golgi for these molecules
(see Figure 2). Figure 4 shows the amount of BB7.2 on these phosphorimager scans is due toa weaker asso-
ciation with b2m. To examine this, pulse±chase experi-and UCSF2-immunoprecipitable forms expressed as a
percentage of the total radiolabeled heavy chain over ments were conducted using W6/32, an antibody whose
epitope is well documented to require the associationthe chase period. For A2.1 (Figure 4A), there appears to
be a precursor product relationship between the UCSF2 of b2m. Phosphorimager scans of the resulting immuno-
precipitates on long exposures revealed a distinct b2mforms and the BB7.2-reactive forms. As a function of
time, there is a decreasein the amount of UCSF2-detect- band as well as the same trafficking pattern previously
determined from pulse±chase experiments using BB7.2able forms that corresponds to the increase in BB7.2-
detectable forms. This represents the formationof heavy (data not shown). Further, we metabolically labeled
C1R±A2.1 and C1R±T134K for 1 hr followed by immuno-chain±b2m±peptide complexes, followed by their trans-
port through the trans±Golgi network to the cell surface. precipitation using BB7.2 and resolved the complexes
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Figure 5. Determination of the Ratio of Heavy Chain to b2M in C1R±
A2.1 and C1R±T134K
C1R±A2.1 and C1R±T134K were metabolically labeled for 1 hr. Class
I complexes were immunoprecipitated from the resulting lysates
using the conformation-sensitive antibody BB7.2. Immunoprecipi-
tates were resolved on 12% SDS±PAGE gels under reducing condi-
Figure 4. Quantitation of the Amount of BB7.2-Reactive Forms Ver- tions. Shown are the resulting phosphorimage scans of the gels.
sus the UCSF2-Reactive Forms Over Time Shown below the scan is the ratio of heavy chain to b2m calculated
by quantitation of the number of pixels contained within each band.Quantitation of the phosphorimage scans shown in Figure 3. (A)
C1R±A2.1, (B) C1R±T134K, and (C) T2 show the percentage of the
total immunoprecipitate that is reactive with either BB7.2 (closed
bars) or UCSF2 (open bars) for each of the chase timepoints. Radio- C1R±A2.1. Both cell lines, however, produced compara-
labeled bands were quantitated using ImageQuant software and ble levels of FMP as determined by Western blotting
percent of total calculated as follows: (BB7.2 pixels[0 band 11 band1 2 band]) / using anti-matrix antibody (data not shown). Therefore,(BB7.2 pixels[0 band 11 band 12 band]) 1 (UCSF2 pixels[0 band 11 band 12 band]) 3 100.
mutation of position 134 effects the ability of the mole-
cule to present viral-derived antigen while leaving the
presentation of exogenously delivered peptide unaf-
using SDS±PAGE (Figure 5). Quantitation of the heavy fected.
chain and b2m bands shows that the ratio of heavy chain
to b2m is 11.4 and 11.7 for A2.1 and T134K, respectively. TAP-Independent Delivery of Peptide into
These data argue that there is no alteration in associa- Endoplasmic Reticulum
tion of b2m with T134K compared with A2.1. MHC class I molecules gain access to endogenous anti-
gen within the ER. Delivery of antigen across the ER
membrane is facilitated by the TAP complex. To investi-Presentation of Viral-Derived Antigen to CTL
To determine theeffect of theT134K mutation onantigen gate whether direct delivery of peptide into the ER would
affect the antigen presentation capabilities of T134K,presentation, C1R±T134K, C1R±A2.1, and the control
cell line C1R±neo were assayed for their ability to pres- we utilized minigene constructs encoding either the
HIV-1 pol peptide alone (Pol) or HIV-1 pol peptide pre-ent the Influenza A matrix epitope (FMP[58±66]) to A2.1-
restricted FMP(58±66)-specific CTL (Figure 6). Both ceded by a signal sequence (Sig/Pol) (Figure 7). We used
minigenes encoding the HIV-1 pol peptide rather thanC1R±A2.1 and C1R±T134K were lysed efficiently after
incubation with FMP(58±66) peptide (Figure 6A). There the influenza A matrix peptide because FMP peptide
can gain access to the ER in the absence of a signalwas no apparent difference in the recognition of C1R±
T134K versus C1R±A2.1 over the range of peptide con- sequence (Zweerink et al., 1993). The hydrophilic HIV-1
pol peptide is unlikely to gain access to the ER in thiscentrations tested. However, recognition of influenza
A±infected C1R±T134K by FMP(58±66)-specific CTL manner. Similar to the results with FMP peptide (see
Figure 6A), there was no difference in the ability of T134Kwas dramatically reduced compared with infected C1R±
A2.1. (Figure 6B). The level of lysis of virus-infected and A2.1 topresent HIV-1 pol peptide toantigen-specific
CTL (data not shown). Minigene constructs expressingC1R±T134K was only 25% of that observed for infected
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Figure 7. Presence of Signal Sequence Rescues Ability of T134KFigure 6. Exogenous Addition of Peptide to T134K-Expressing Cells
Results in Wild-Type Levels of Lysis, While Infection with Influenza to Present Endogenously Derived Antigen
A Shows Significantly Reduced Levels C1R±A2.1, C1R±T134K, and C1R±neo were transfected with p8901
constructs expressing HIV-1 pol peptide (Pol), HIV-1 pol peptide(A) The ability of A2.1-restricted FMP(58±66)-specific CTL to recog-
nize targets expressing A2.1, neo, or T134K upon exogenous addi- preceded by signal sequence (Sig/Pol), or vector alone, p8901. Abil-
ity of A2.1-restricted HIV-1 pol±specific CTL to recognize thesetion of FMP(58±66) peptide was determined. FMP(58±66) peptide
was added in 10-fold increments from 0.01±100 nM. Percent specific transfectants was determined using standard 51Cr release assays.
Sig/Pol (closed bars), Pol (stippled bars), p8901 vector control (openlysis is shown for each target. C1R±A2.1 (closed squares), C1R±
T134K (closed squares, dashed lines), and C1R±neo (closed circles) bars) not done for neo.
negative control.
(B) A2.1-restricted FMP(58±66)-specific CTL were tested for their
ability to lyse A2.1, T134K, or neo expressing targets after infection the absence of signal sequence suggests a defect in
with influenza A virus AX/31. Targets were infected with virus and
TAP-dependent peptide loading.allowed to express viral proteins for 4 hr prior to incubation with
effectors. Closed bars represent the percent specific lysis relative
to A2.1.
Quantitation of Intracellular Peptide Loading
The ability of the T134K cell line to load peptide in a
TAP-dependent manner was further examined using thePol, Sig/Pol, or vector alone (p8901) were transfected
into C1R±A2.1, C1R±T134K, and C1R±neo. CTL assays streptolysin O system of intracellular peptide loading.
This method relies on the permeabilization of the cellwere done using A2.1-restricted HIV-1 pol±specific CTL.
Recognition of C1R±A2.1 and C1R±T134K transfected membrane using streptolysin O, followed by incubation
with iodinated peptide that is then transported into thewith the minigene constructs was dramatically different.
C1R±T134K expressing Pol failed to be lysed above the ER in a TAP-dependent manner. This enables the TAP-
dependent loading of class I molecules with the radiola-level of the control cell line, C1R±neo, in contrast with
the efficient lysis observed for C1R±A2.1 expressing Pol. beled peptide (Neefjes et al., 1993; Androlewicz et al.,
1993). The amount of TAP-dependent peptide loadingThere was no difference in the ability of the HIV-1 pol±
specific CTL to recognize C1R±A2.1 expressing the is determined by measurement of the level of incorpora-
tion of radiolabeled peptide into W6/32-reactive class IHIV-1 pol peptide in the presence or absence of the
signal sequence. However, the failure of C1R±T134K to complexes. The amount of iodinated HIV-1 pol peptide
associated with A2.1, T134K, and control HLA-B35 (B35)be recognized by the CTL was restored by transfection
of these cells with Sig/Pol. Similar results were obtained reveals a substantial difference in the ability of T134K
and A2.1 to load peptide in a TAP-dependent mannerusing four different transfected cell lines, indicating that
this result was not due to clonal variation. These mini- (Figure 8). The level of binding of HIV-1 pol peptide by
T134K is only 7% of that observed for A2.1. The controlgene constructs allow the delivery of peptide into the
ER in a TAP-independent or TAP-dependent manner cell line C1R transfected with HLA-B35 shows less than
1% peptide binding relative to A2.1. The low level ofas a result of the presence or absence of the signal
sequence. Determination of specific amounts of HIV- association of T134K with the iodinated HIV-1 pol pep-
tide cannot be explained by a functional defect in T134Kpol peptide that gain access to the ER during the course
of these experiments is not possible. Consequently, it rendering the molecule incapable of peptide binding,
because addition of HIV-1 pol peptide exogenouslyis a formal possibility that an increased concentration
of HIV-pol peptide in the ER could compensate for an (data not shown) or transfection with signal sequence/
HIV-1 pol constructs (see Figure 7) results in sensitiza-inherent defect inC1R±T134K, such as reduced associa-
tion with b2m. The ability to sensitize C1R±T134K for tion for lysis by HIV-1 pol±specific CTL. Further, binding
of HIV-pol peptide can be detected in lysate bindinglysis by transfection with Sig/Pol means that T134K does
not have a global defect in intracellular peptide loading. assays monitoring either increase in conformational
heavy chain or incorporation of radiolabeled peptideFurthermore, the failure of the HIV-1 pol±specific CTL
to lyse C1R±T134K expressing the HIV-1 pol peptide in (data not shown). In addition, the thermostabilities of
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a band of relative molecular mass of 45 kDacorrespond-
ing to the class I heavy chain. Anti-TAP immunoprecipi-
tates from C1R±T134K also contain the 48 kDa band;
however, the 45 kDa band corresponding to the class I
heavy chain is absent. Identical results were found with
the R.RING4C antiserum (data not shown). A variety
of labeling times ranging from 3±15 min gave identical
results (data not shown). These immunoprecipitates re-
veal the lack of detectable association of T134K with
the TAP complex.
Discussion
In summary, the effect of mutation of threonine 134 to
lysine in the A2.1 molecule is to render the heavy chain
incapable of interacting with the TAP complex. This re-
Figure 8. T134K Shows a Dramatic Reduction in the Ability to Intra- sults in decreased cell surface expression, as well as
cellularly Load Peptide as Compared with A2.1
altered intracellular trafficking of the molecules. Func-
Intracellular loading of 125I-labeled HIV-pol peptide in C1R±A2.1,
tionally, there is a dramatic decrease in the ability of theC1R±T134K, or C1R±B35 expressing permeabilized cells. C1R±B35
class I molecule to present viral-derived antigen. Directserves as negative control. Assays were performed in duplicate.
delivery of peptide to the ER in a TAP-independent man-Replicate 1, closed bars; replicate 2, open bars.
ner restores the ability of C1R±T134K to serve as target
for peptide-specific CTL. Furthermore, analysis of the
ability of T134K to bind peptide in a TAP-dependentA2.1 and T134K when bound to the HIV-pol peptide
manner, utilizing the streptolysin O system, indicatesare identical (E. Collins and J. A. F., unpublished data).
that T134K cannot achieve a productive association withThese data argue strongly that the T134K mutation does
the TAP complex. Finally, T134K heavy chain cannot benot affect peptide binding directly.
demonstrated to associate with the TAP complex in
radiolabeled immunoprecipitates.Association of Heavy Chain with the TAP Complex
The phenotype of C1R±T134K was reminiscent of T2Digitonin extracts of metabolically labeled A2.1, T134K,
cells, which, due to a chromosomal deletion, lack theT2 cell lines were immunoprecipitated with BB7.2,
genes encoding the TAP complex. T134K and T2 botha-TAP, and UCSF2. Immunoprecipitates were treated
express lowered levels of A2.1on the cellsurface and failwith endo H and separated using SDS±PAGE. Figure 9
to present endogenously synthesized peptide to CTL.shows the phosphorimage scan of an SDS±PAGE gel
Intracellular trafficking of the A2.1 molecule is also af-used to resolve the immunoprecipitates. There is a 2.5-
fected by the mutation. T134K molecules exhibit an al-fold difference in the amount of BB7.2-precipitable
tered transport rate from both the ER to the cis±Golgiheavy chain±b2m±peptide complexes in C1R±T134K
as well as to the trans±Golgi. Analysis of the rate ofcompared with C1R±A2.1 (Figure 9, lanes 1 and 4). How-
transport determined by acquisition of endo H resis-ever, there is 50% more total heavy chain labeled within
tance or sialylation suggests that the T134K moleculesthe 5 min period in C1R±T134K than in C1R±A2.1 (Figure
transit faster than the A2.1 molecules. Correspondingly,9, lanes 3 and 6). Figure 9, lane 2, containing the a-TAP
A2.1 molecules expressed by T2 cells also have an ap-immunoprecipitates from C1R±A2.1, shows a previously
parent increased rate of intracellular trafficking whendescribed 48K (Ortmann et al., 1994) band, as well as
compared with A2.1 expressed by C1R. C1R±T134K is
also characterized by a lossof heavy chain±b2m±peptide
complexes throughout the transport process. It is un-
likely that this decay of complexes is due to an altered
association with b2m inherent to T134K. This is sup-
ported by experiments showing identical trafficking pat-
terns for complexes immunoprecipitated with either
BB7.2 or W6/32. Further, the ratio of heavy chain to b2m
in immunoprecipitates from both C1R±A2.1 and C1R±
T134K is virtually identical.
Experiments involving sequential immunoprecipita-
Figure 9. T134K Fails to Coimmunoprecipitate with TAP Complex tion reveal a precursor product relationship between
in Radiolabeled Lysates UCSF2-precipitable forms and BB7.2 forms in the case
Cells (1 3 107) per lane were metabolically labeled using 35S transla- of A2.1. There is a decrease in UCSF2-reactive forms
bel for 5 min followed by lysis and immunoprecipitation using the coordinate with an increase in BB7.2-reactive forms
conformation-sensitive antibody BB7.2 (lanes 1 and 4), a-TAP anti- over the chase period. This decrease in UCSF2-reactive
sera directed against a carboxy-terminal peptide of TAP1 (lanes 2
forms indicates formation of heavy chain±b2m±peptideand 5) or UCSF2 antisera directed against a carboxy-terminal pep-
complexes, which become BB7.2 reactive. In the casetide of HLA-A2.1 (lanes 3 and 6). Each of the samples was endo H-
digested prior to separation by 12% SDS±PAGE. of T134K and A2.T2, this precursor product relationship
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exists only at very early timepoints (less than 30 min). lysis by peptide-specific CTL. In addition, experiments
using a peptide±MHC complex±specific monoclonal an-Furthermore, only a fraction of the total molecules de-
tibody indicate that hepatitis B virus peptide±T134Ktectable by BB7.2 or W6/32 in T134K and T2 (W6/32;
complexes are as stable as hepatitis B virus peptide±Baas et al., 1992) at early chase timepoints are fully
A2.1 complexes on the cell surface (data not shown).sialyated. This is evident by the decrease in BB7.2 or
Finally, the T134K mutation, a substitution of a chargedW6/32-immunoprecipitable forms. The loss of these
for a polar residue in a solvent-exposed loop away fromcomplexes is not accountable for by simple degradation
any intramolecular interactions, would not be expectedof heavy chain because of the coordinate increase in
to alter the structure of the molecule. Taken together,UCSF2-precipitable forms. Rather, this decrease is the
these data suggest that the antigen presentation defectresult of the loss of the epitope for the BB7.2 and W6/
in T134K is not due to an inability to bind peptide, or to32 antibodies. BB7.2 recognizes an epitope in a1 and
an intrinsic instability of the T134K±peptide complex.a2 helix, suggesting that loss of this epitope reflects the
Class I heavy chain±b2m complexes have been shownloss of peptide. It is well documented that the W6/32
to associate with the TAP complex (Ortmannet al., 1994;epitope is dependent on the heavy chain association
Suh et al., 1994). It is thought that this association facili-with b2m. Loss of this epitope suggests that loss of b2m
tates peptide loading. Immunoprecipitation using TAPmust have taken place. Furthermore, experiments in the
antisera revealed the presence of TAP±heavy chain±b2mTAP-negative T2 cell line have documented a loss of
complexes in the A2.1-expressing cell line. However, nob2m from the W6/32 immunoprecipitates, which suggest
TAP±heavy chain±b2m complexes were detectable inthat the molecules in T2 are intrinsically less stable (Baas
C1R±T134K or T2 cells (data not shown). Overall, theseet al., 1992). Experiments described here show that
results strongly suggest that T134K fails to load peptideheavy chain±b2m±peptide complexes immunoprecipi-
in a TAP-dependent manner. This is further supportedtated from both C1R±T134K and T2 decrease over time,
by the functional data obtained from minigene experi-indicating that these complexes are less stable than the
ments. These results show that the presence of an ERcorresponding complexes in C1R±A2.1. In the case of
signal sequence, which enables TAP-independent load-T134K, the loss of the W6/32 epitope may be a result
ing, restores recognition of C1R±T134K by CTL.of the loss of peptide, which causes the decay of the
The TAP interaction site on the class I molecule istrimeric complex, as suggested by the loss of BB7.2
likely to involve many residues. It is also likely that there
reactivity. The percentage of BB7.2 forms that are fully
are species-specific as well as allelic differences in the
sialylated in C1R±T134K compared with C1R±A2.1 at
interaction with the TAP complex. Recent experiments
extended chase times agrees with the level of BB7.2
have shown a dependence upon the presence of the
complexes detectable at the cell surface. Similarly, W6/
transmembrane region and cytoplasmic tail of the hu-
32-precipitable forms of A2.1 in T2 at extended chase
man class Ib antigen HLA-G for interaction with the TAP
timepoints is comparable to the levels expressed at the complex (Lee et al., 1995). In the absence of TAP, both
cell surface (Baas et al., 1992). the membrane-bound and secreted form of HLA-G are
Functionally, recognition of influenza-infected C1R± expressed or secreted at lower levels. However, the
T134K by FMP-specific CTL is dramatically reduced, spectrum of peptides associated with the membrane-
suggesting a defect in the ability to present endoge- bound or soluble form is qualitatively the same. This is
nously derived antigen. Clarification of the nature of the in sharp contrast with the A2.1 molecule expressed in
inability to present endogenously derived antigen in T2 the absence of the TAP complex. Analysis of the pep-
cells comes from experiments using minigene con- tides associated with the A2.1 complex in the absence of
structs (Zweerink et al., 1993). These minigene con- TAP reveal a predominance of signal sequence-derived
structs enable peptide delivery into the ER in a TAP- peptides that acquire access to the ER in a TAP-inde-
independent or TAP-dependent manner as a result of pendent manner (Henderson et al., 1992; Wei and Cress-
the presence or absence of the signal sequence. In T2, well, 1992). Therefore, in the case of A2.1, the TAP com-
this defect can be overcome by transfection with mini- plex is critical to the spectrum of peptides that are
gene constructs, which express a peptide of appropriate presented. Given that the primary site of expression of
length and restriction preceded by an ER signal se- HLA-G is at the maternal placental interface, it is possi-
quence. C1R±T134K is reminiscent of T2 in that the ble that theability tobind thesame spectrumof peptides
presence of a signal sequence preceding the HIV-1 pol by either form plays a critical role in the as yet undefined
peptide rescues the ability of C1R±T134K to be recog- function of the HLA-G molecule. In contrast, experi-
nized by CTL. ments by Carreno et al. (1995) show that a soluble form
The data presented here support an involvement of of Ld is capable of association with the TAP complex in
the TAP complex in the phenotype of C1R±T134K. mouse. Further, mutation of the a3 residue 227 of the Ld
Therefore, we examined TAP-dependent loading in molecule ablates the interaction with the TAP complex
C1R±T134K. Quantitation of intracellular peptide loading while failing to reduce levels of cell surface expression.
shows that the level of peptide binding to T134K is only It is unclear, however, whether or not this levelof expres-
7% that of A2.1. This suggests that T134K fails to bind sion is reflective of the inherent nature of Ld to be
peptide in a TAP-dependent manner. This cannot simply expressed under less than ideal conditions. Also, the
be explained by the inability of T134K to bind peptide, functional manifestations in terms of presentation of
because functional experiments using the same epi- viral-derived antigen have yet to be explored.
tope as well as two other epitopes, FMP(58±66) and The results of these experiments have served to char-
HIV-p17 gag (data not shown), show that addition of acterize the phenotype of C1R±T134K in both a func-
tional and biochemical manner. They may also provideexogenous peptide efficiently sensitizes C1R±T134K for
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fluorescence intensity (MFI) of each cell line was measured anda possible explanation for the conservation of threonine
standardized as the percent cell surface expression relative to C1R±134 among species. These experiments demonstrate
A2.1 by the following formula: Percent relative expression 5 ([MFIC1Rthe importance of the threonine at position 134 of the
A2 mutant 2 MFIC1R neo]/[MFIC1R wild-type A2 2 MFIC1R neo]) 3 100.A2.1 molecule in the interaction with the TAP complex.
Whether this mutation affects the interaction with the Pulse±Chase Labeling and Immunoprecipitations
TAP complex directly or indirectly through an as yet Pulse±chase labeling and immunoprecipitations were performed as
undefined accessory molecule has not been deter- described by Hill et al. (1993) using 10 mg of purified antibody and
a 5 min metabolic labeling period. Sequential immunoprecipitationsmined. Support for the role of additional proteins in the
of pulse±chase-labeled samples were performed as described ex-interaction between the TAP complex and class I comes
cept for the addition of an extra incubation with proteinA±Sepharosefrom experiments involving analysis of the 721.220 cell
beads between antibodies to ensure removal of all antibody com-
line (Grandea et al., 1995). Class I heterodimers in this plexes. Secondary immunoprecipitation was accomplished by incu-
cell line fail to associate with the TAP complex as a bation of supernatantswith 7.5 ml of UCSF2antisera. Immunoprecip-
result of the absence of an as yet unidentified molecule. itations of TAP±heavy chain±b2m complexes from radiolabeled
lysates were conducted as previously described (Ortmann et al.,Further, the consistent presence of the 48 kDa protein
1994) Radiolabel periods were 3, 5, or 15 min.in TAP immunoprecipitates as first detected by Ortmann
et al. (1994) and shown here in Figure 9 suggests that
Endo H Digestion and SDS±PAGEat least one additional protein associates with the TAP±
Prior to endo H digestion, immunoprecipitates were boiled for 5 min
class I complex. Determination of the role, if any, of this in 0.1 M b-mercaptoethanol, 0.1% SDS. Samples were then divided
protein in the class I presentation pathway should prove equally and sodium citrate was added to a final concentration of
quite interesting. This first description of a heavy chain 75 mM. Samples were digested 12 hr at 308C with 4 U of endo H
(Boerhinger Mannheim) or mock digested with an equivalent volumemutant that selectively affects TAP-dependent peptide
of H2O. Samples were analyzed by electrophoresis by the methodloading underscores thevery crucial nature of structure±
of Laemmli (1970) using 12% SDS±PAGE under reducing conditions.function relationships among the components involved
in antigen presentation.
IEF
One-dimensional IEF was performed essentially as described by
Experimental Procedures (Neefjes et al., 1986). The gel composition was 9.1 M urea, 2% (v/v)
NP-40, 4.5% (w/v) polyacrylamide (30:1.6 monoacrylamide:bisacry-
Cell Lines lamide), 4% (v/v) ampholytes 5±7, 1% (v/v) ampholytes 3.5±10 and
Mutant T134K was constructed as previously described (Moots et 0.6% (v/v) ampholytes 7±9 (Pharmacia Biotech, Piscataway, New
al., 1991). HLA-A2.1 mutants are designated using the wild-type Jersey). Cation solution was 50 mM NaOH and anode solution was
amino acid (threonine) followed by the position (134) and the mutant 20 mM H3PO4. IEF was performed for 15 hr.amino acid (lysine). HMy2.C1R (C1R) (Storkus et al., 1987), a human
cell line that expresses HLA-C, reduced levels of HLA-B, but no
PeptidesHLA-A, was cotransfected with T134K (C1R±T134K), or HLA-A2.1
The HLA-A2.1-restricted HIV-1 pol epitope (residues 461±485, IL-(C1R±A2.1) and pSV2±neo by electroporation as previously de-
KEPVHGV) and the influenza A matrix epitope, FMP(58±66) (residuesscribed (Moots et al., 1991). C1R±neo cell line contains pSV2±neo
58±66, GILGFVFTL) were synthesized by Dr. D. Klapper (Universityalone. p8901 transfectants were generated from these existing cell
of North Carolina, Chapel Hill, North Carolina). All peptides werelines by electroporation with either the p8901 construct, p8901 en-
purified by reversed phase HPLC.coding the HIV-1 pol peptide (MILKEPVHGV) with or without the
signal sequence as previously described (Zweerink et al., 1993).
Generation of CTL Lines
Generation of HLA-A*0201-restricted FMP(58±66) cytotoxic T lym-Antibodies
phocyte line was as previously described (McMichael et al., 1988).Monoclonal antibodies used were the following: BB7.2, HLA-A2.1
Generation of HIV-1 pol±specific CTL line was as previously de-specific, recognizes a determinant in a2 (Parham and Brodsky,
scribed (Pogue et al., 1995).1981); HCA2, which recognizes HLA-A heavy chains (H. Ploegh,
personal communication); UCSF2, a peptide antisera directed
against a carboxy-terminal peptide of HLA-A2.1, which also cross- CTL Assays
reacts with other HLA alleles (Guagliardi et al., 1990). W6/32 (Barn- CTL recognition of target cells that were either virally infected,
stable et al., 1978) recognizes heavy chain±b2m±peptide complexes. transfected with p8901 constructs (gift of H. Zweerink), or incubated
a-TAP, a peptide antisera that recognizes an epitope in the carboxyl with specific peptides was measured using standard in vitro 51Cr
terminus of TAP1. This antiserum was prepared essentially as pre- release assays. Targets were labeled with 51Cr for 1 hr, washed, and
viously described using a peptide encoded in the carboxyl terminus plated in wells of a round-bottomed 96-well at 1 3 104 cells/well
of TAP1 (Kelly et al., 1992). In brief, 1.5 mg of peptide (GCYWAMVQA with or without CTL at an effector:target (E:T) ratio of 1:1. FMP(58±66)
PADAPE) cross-linked to keyhole limpet hemocyanin with 1-ethyl- peptide was then added to the appropriate wells at various concen-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) was trations. Assays utilizing p8901 transfectants were carried out in the
used to immunize a New Zealand White rabbit. Serum used was same manner except there was no addition of peptide. After a 4 hr
taken after the fourteenth injection of antigen. The specificity of this incubation at 378C, 5% CO2, supernatants were harvested using a
antiserum was confirmed by Western immunoblotting of lysates Skatron harvesting system (Skatron Instruments, Sterling, Virginia)
from normaland TAP-deficient cell lines (data not shown). R.RING4C and the amount of radiolabel released determined using a Packard
TAP antisera has been previously described (Ortmann et al., 1994). g counter (Packard, Sterling, Virginia). All assays were performed in
duplicate. Assays utilizing the HIV-pol peptide were performed as
described above except that the target cells were preincubated withFlow Cytometry
Cells (106) were stained using either purified antibody or overgrown peptides at appropriate concentrations for 1 hr prior to addition of
effectors.hybridoma supernatants as the primary antibody followed by detec-
tion using a goat anti-mouse immunoglobulin G fluoresceinated 51Cr-labeled target cells were infected or mock infected with influ-
enza A by the addition of virus (1±2 HAU/100 cells) or media onlyantibody. A minimum of 5000 total events were analyzed using a
FACScan flow cytometer (Becton Dickinson, San Jose, California). as appropriate. Targets were then incubated for 3 hr in RPMI 1640
containing 10% fetal calf serum at 378C and subsequently washedAnalysis of the data was performed using the computer program
Cicero (Cytomation, Fort Collins, Colorado). The mean of the linear and plated as previously described. C1R±A2.1, and C1R±neo were
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positive and negative controls, respectively, for each assay. Per- J., Korn, N., Sidwell, B., and Orr, H. (1985). Mutations that impair a
posttranscriptional step in expression of HLA-A and -B antigens.centage specific lysis was calculated according to the formula:
Percent specific lysis 5 ([cpmsample 2 cpmspontaneous) / (cpmmaximum 2 Proc. Natl. Acad. Sci. USA 82, 8183±8187.
cpmspontaneous]) 3 100. Spontaneous release is the amount of radioac- Deverson, E.V., Gow, I.R., Coadwell, W.J., Monaco, J.J., Butcher,
tivity released by target cells in the absence of effectors, and maxi- G.W., and Howard, J.C. (1990). MHC class II region encoding pro-
mum release is the amount of radioactivity released by target cells teins related to the multidrug resistance family of transmembrane
lysed with 5% Triton X-100. The percent relative lysis was calculated transporters. Nature 348, 738±741.
using the formula: Percent relative lysis 5 ([Percent specific lysisA2 Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee,
mutant 2 percent specific lysisC1R±neo) / (percent specific lysisC1R±A2 2 H.G. (1991). Allele-specific motifs revealed by sequencing of self-
percent specific lysisC1R±neo]). peptides eluted from MHC molecules. Nature 351, 290±296.
Germain, R. (1994). MHC-dependent antigen processing and pep-
Intracellular Peptide Loading Assay
tide presentation: providing ligands for T lymphocyte activation. Cell
Cells were permeabilized with streptolysin O and intracellular load-
76, 287±299.
ing of peptide was performed as previously described (Tussey et
Grandea, A., Androlewicz, M., Athwal, R., Geraghty, D., and Spies,al., 1995). In brief, 2 3 107 cells were permeabilized with streptolysin
T. (1995). Dependence of peptide binding by MHC class I moleculesO and incubated with 2 3 107 cpm of 125I-labeled HIV-pol peptide.
on their interaction with TAP. Science 270, 105±108.Iodination of peptides was carried out as previously described (An-
Guagliardi, L., Koppelman, B., Blum, J., Marks, M., Cresswell, P.,drolewicz et al., 1993). Incubation with peptide was carried out for
and Brodsky, F. (1990). Co-localization of molecules involved in10 min. Cells were then washed and lysed in 1 ml of lysis buffer
antigen processing and presentation in an early endocytic compart-containing 1% Triton X-100, 0.15 M NaCl, 0.01 M Tris±HCl (pH 7.4),
ment. Nature 343, 133±139.5 mM iodoacetamide, 0.5 mM phenylmethylsulfonyl fluoride, and
additionally 10 mM of unlabeled HIV-pol peptide to prevent further Henderson, R.A., Michel, H., Sakaguchi, K., Shabanowitz, J., Ap-
binding of labeled peptide after solubilization. Cell lysates were pella, E., Hunt, D.F., and Engelhard, V.H. (1992). HLA-A2.1-associ-
clarified by centrifugation at 10,000 3 g for 5 min, and class I heavy ated peptides from a mutant cell line: a second pathway of antigen
chain±b2m±peptide complexes were immunoprecipitated by addi- presentation. Science 255, 1264±1266.
tion of 10 mg of W6/32. The level of bound 125I-labeled peptide was Hill, A., Takiguchi, M., and McMichael, A. (1993). Different rates of
determined by counting in a g counter (LKB Compugamma CS). HLA class I molecule assembly which are determined by amino acid
sequence in the alpha 2 domain. Immunogenetics 37, 95±101.
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